Profitability
This table compares NeurAxis and Guided Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -492.76% | N/A | -641.25% |
Guided Therapeutics | N/A | N/A | -151.93% |
Earnings and Valuation
This table compares NeurAxis and Guided Therapeutics”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
NeurAxis | $2.46 million | 6.75 | -$14.63 million | ($1.84) | -1.26 |
Guided Therapeutics | $100,000.00 | 66.06 | -$3.49 million | ($0.03) | -3.32 |
Guided Therapeutics has lower revenue, but higher earnings than NeurAxis. Guided Therapeutics is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Institutional and Insider Ownership
11.8% of NeurAxis shares are held by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are held by institutional investors. 15.2% of NeurAxis shares are held by insiders. Comparatively, 66.8% of Guided Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Guided Therapeutics beats NeurAxis on 6 of the 10 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.